Last reviewed · How we verify
NCT04473300
Assessment of Lung Recruitablity of Acute Respiratory Distress Syndrome With SARS-CoV-2 Pneumonia by Electrical Impedance Tomography
trial in Critical Illness in 43 participants. Completed in 28 February 2021.
28 February 2021
Quick facts
| Lead sponsor | Osaka University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 43 |
| Start date | 11 May 2020 |
| Primary completion | 28 February 2021 |
| Estimated completion | 28 February 2021 |
| Sites | 1 location across Japan |
Conditions studied
- Critical Illness — all drugs for Critical Illness →
- ARDS — all drugs for ARDS →
Sponsor
Osaka University
Who can join
18 and older, any sex, with Critical Illness or ARDS. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Novel coronavirus (SARS-CoV-2: severe acute respiratory coronavirus 2) pneumonia often develop the acute respiratory distress syndrome (ARDS). Lung protective ventilation strategy consisting of low tidal volume and high positive end-expiratory pressure (PEEP) is recommended. However, it is not clear whether injured lungs from SARS-CoV-2 pneumonia have the same mechanical properties, especially response to PEEP as common ARDS. Therefore, the investigators propose an observational study to analyze respiratory mechanics and lung recruitablity using EIT (electrical impedance tomography) in patients with ARDS due to SARS-CoV-2 pneumonia.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04473300
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Critical Illness
Currently open trials in the same condition.
- NCT06189924 — Exhaled Breath Condensate Analysis in Mechanically Ventilated Patients · recruiting
- NCT07418242 — Prognostic Value of Novel Biomarkers on Adverse Renal Outcomes in High-Risk Cardiac Surgery Patients · recruiting
- NCT07101640 — PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysp · Phase 1, PHASE2 · recruiting
- NCT07177183 — Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning Failure · NA · recruiting
- NCT07369258 — Clinical Application of Listening to Music to Prevent Delirium in the Intensive Care Unit · NA · recruiting
Other Osaka University trials
Trials by the same sponsor.
- NCT06924151 — Isolated Surgical Aortic Valve Replacement in Low Risk AS Patients · NA · recruiting
- NCT06826027 — TAV-in-SAV in Japanese Patients · active not recruiting
- NCT06441994 — Clinical Trial of Targeted Alpha Therapy Using [At-211]PSMA-5 for Prostate Cancer · Phase 1 · recruiting
- NCT05939661 — A Multicenter Single-arm P2 to Evaluate Safety and Efficacy of the Total Neoadjuvant Therapy for cT2 Rectal Cancer · Phase 2 · recruiting
- NCT05350098 — Efficacy of Plant-protein Diets in Patients With Chronic Kidney Disease · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04473300 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Osaka University
- Last refreshed: 1 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04473300.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing